<DOC>
	<DOC>NCT02301130</DOC>
	<brief_summary>Mogamulizumab in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors</brief_summary>
	<brief_title>Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Age â‰¥ 18 years; Locally advanced or metastatic solid tumors; Histologically or cytologically confirmed disease; Failed or were intolerant to at least one prior systemic treatment regimen with oral or IV medications and have no additional therapy options known to prolong survival. Subjects with nonsmall cell lung cancer must have received at least one platinum doublet regimen. Subjects with known epidermal growth factor receptor tyrosine kinase inhibitor activating mutations or anaplastic lymphoma kinase rearrangement must have also exhausted approved targeted therapy options; Any concurrent chemotherapy, biologic, hormonal, radiation, or investigative therapy for cancer treatment within 21 days prior; Concurrent or prior use of immunosuppressive medication within 28 days; Active or prior documented autoimmune or inflammatory bowel disease within 3 years with some exceptions; Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>advanced solid tumors</keyword>
	<keyword>solid tumors</keyword>
	<keyword>mogamulizumab</keyword>
	<keyword>non-small cell lung</keyword>
	<keyword>pancreatic</keyword>
	<keyword>head and neck</keyword>
</DOC>